Drug intelligence / Profile preview

BMS-986315 + cetuximab

Development stage: Discontinued
Lead developer: Bristol Myers Squibb
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BMS-986315 + cetuximab is a combination therapy consisting of BMS-986315 (an anti-NKG2A monoclonal antibody) and cetuximab (an EGFR inhibitor). BMS-986315 is a fully human IgG1.3 monoclonal antibody that binds to human natural killer group 2 member A (NKG2A), blocking the interaction of natural killer cells with this receptor. This may allow the body to mount a more robust anti-cancer immune response. Cetuximab works by blocking the epidermal growth factor receptor (EGFR), which helps slow cancer growth. This combination was investigated for the treatment of advanced solid tumors.

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)KLRC1 (Killer cell lectin-like receptor subfamily C member 1)

Beyond the preview

Go deeper on BMS-986315 + cetuximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-986315 + cetuximab.

Explore the full profile